Continuous Glucose Monitoring, Contingency Management, and Motivational Interviewing for Patients With Type 2 Diabetes in Kansas City (COMMITTED2-KC)

January 5, 2026 updated by: University of Missouri, Kansas City

COntinuous Glucose Monitoring, Contingency Management, and Motivational InTerviewing for Patients With TypE 2 Diabetes in Kansas City

This study is evaluating a behavioral treatment program that uses diabetes coaching and financial rewards in addition to continuous glucose monitoring to improve diabetes management in adult patients with type 2 diabetes. This study will evaluate if this behavioral treatment program increases individual adherence to a diabetes treatment plan and improves blood sugar management.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

A randomized parallel-group pilot study of a combination intervention using Motivational Interviewing (MI) and Contingency Management (CM) for patients with T2DM. Individuals will be randomized in a 1:1 ratio to the intervention group or the control group. Randomization will be blocked and stratified by long-acting insulin and GLP1 medication use. All participants will be given a Continuous Glucose Monitor (CGM) to assess real-time blood sugar levels and establish CM rewards for those assigned to the treatment group.

Study Type

Interventional

Enrollment (Actual)

26

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Missouri
      • Kansas City, Missouri, United States, 64108
        • University of Missouri - Kansas City School of Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Diagnosed with type 2 diabetes
  2. Age 18 to 65
  3. Hemoglobin A1c (blood draw or point-of-care) test available within the last 3 months
  4. Most recent hemoglobin A1c result between 8.0 and 11.0
  5. Currently receiving treatment for diabetes by a licensed healthcare provider.
  6. Reliable access to a personal smart phone that is compatible with CGM
  7. English speaking

Exclusion Criteria:

  1. Type 1 diabetes
  2. Secondary type 2 diabetes (diagnosis secondary to other medical conditions such as pancreatitis, Cystic Fibrosis, or Cushing disease)
  3. Prescribed short-acting (mealtime) insulin as part of diabetes treatment plan
  4. Known or acknowledged active substance use disorder or that would interfere or negatively impact participation in the study
  5. Diagnosis of a medical/psychiatric condition that would prevent participation in the study (e.g., Intellectual Disability, Alzheimer's disease, Traumatic Brain Injury, Schizophrenia)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Behavioral Intervention with financial rewards and coaching
Individuals in the treatment group will receive financial rewards (contingency management) and diabetes coaching (motivational interviewing) in addition to wearing a continuous glucose monitor while receiving their usual diabetes treatment.
Behavioral: Behavioral Intervention with financial rewards and coaching
Participants will receive variable financial incentives based on their engagement with the continuous glucose monitor and meeting diabetes treatment goals. In addition, they will participate in three motivational interviewing sessions focused on their diabetes management. Participants will continue to receive their diabetes treatment as usual.
Other Names:
  • Contingency management and motivational interviewing
Active Comparator: Control
Individuals in the control group will not receive any interventions and will only wear a continuous glucose monitor while receiving their usual diabetes treatment.
Behavioral: Control
Participants will only receive a continuous glucose monitor, which they may engage with as desired and no further intervention. Participants in the control group will continue to receive their diabetes treatment as usual.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time in target blood glucose range per CGM
Time Frame: baseline to 14 weeks
Percent time with blood glucose between 70 to 180 mg/dL
baseline to 14 weeks
Hemoglobin A1C
Time Frame: baseline to 12 weeks
laboratory value
baseline to 12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diabetes Quality of Life Brief Inventory
Time Frame: baseline to 12 weeks
self-report questionnaire
baseline to 12 weeks
Diabetes Distress Scale
Time Frame: Baseline to 12 weeks
self-report questionnaire
Baseline to 12 weeks
PROMIS Medication Adherence Scale
Time Frame: Baseline to 12 weeks
self-report questionnaire
Baseline to 12 weeks
Perceived Dietary Adherence Questionnaire
Time Frame: Baseline to 12 weeks
self-report questionnaire
Baseline to 12 weeks
Motivation and Confidence Ruler
Time Frame: Baseline to 12 weeks
self-report questionnaire
Baseline to 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Missouri, Kansas City

Investigators

  • Principal Investigator: Jared Bruce, PhD, University of Missouri, Kansas City

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2024

Primary Completion (Actual)

July 29, 2025

Study Completion (Actual)

August 12, 2025

Study Registration Dates

First Submitted

April 15, 2024

First Submitted That Met QC Criteria

April 15, 2024

First Posted (Actual)

April 18, 2024

Study Record Updates

Last Update Posted (Actual)

January 7, 2026

Last Update Submitted That Met QC Criteria

January 5, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2095072 (Other Identifier: UMKC IRB)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type 2 Diabetes

Clinical Trials on Behavioral Intervention with financial rewards and coaching

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe